Nano-X Imaging (NASDAQ:NNOX – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Profitability
This table compares Nano-X Imaging and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nano-X Imaging | -926.05% | -116.93% | -100.67% |
| NovoCure | -16.78% | -35.81% | -15.14% |
Earnings & Valuation
This table compares Nano-X Imaging and NovoCure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nano-X Imaging | $13.02 million | 1.83 | -$75.02 million | ($2.14) | -0.14 |
| NovoCure | $655.35 million | 2.00 | -$136.23 million | ($1.06) | -10.58 |
Nano-X Imaging has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nano-X Imaging has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Nano-X Imaging and NovoCure, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nano-X Imaging | 1 | 2 | 2 | 1 | 2.50 |
| NovoCure | 1 | 4 | 3 | 0 | 2.25 |
Nano-X Imaging presently has a consensus target price of $4.33, indicating a potential upside of 1,334.88%. NovoCure has a consensus target price of $22.33, indicating a potential upside of 99.21%. Given Nano-X Imaging’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Nano-X Imaging is more favorable than NovoCure.
Institutional and Insider Ownership
21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
NovoCure beats Nano-X Imaging on 9 of the 15 factors compared between the two stocks.
About Nano-X Imaging
Nano-X Imaging Ltd. is an Israeli medical technology company developing digital X-ray imaging systems and related services. Its Nanox.ARC system is designed to produce medical images using the company’s digital X-ray technology, with the goal of expanding access to diagnostic imaging. The company’s broader offering includes Nanox.CLOUD, a cloud-based platform intended to connect imaging systems with image-management and diagnostic services, and Nanox.AI, which develops artificial-intelligence tools for analyzing medical images.
About NovoCure
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.
Receive News & Ratings for Nano-X Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nano-X Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
